The Evergreen Study
Currently Recruiting
26 Aug 2026
Up to $6,300
Melbourne, Australia
This clinical trial is exploring an investigational medication that could help treat autoimmune diseases.
These conditions occur when the immune system mistakenly attacks the body’s own tissues. This can lead to inflammation, joint pain, damage to different parts of the body, and ongoing symptoms that may affect daily life.
In these diseases, certain immune cells called B cells play an important role. They can produce substances that drive inflammation and contribute to tissue damage.
While treatments are available, they do not work for everyone. In some cases, they may not fully remove harmful B cells from the body, meaning symptoms can continue or the disease may not respond well to treatment.
The study drug being tested is designed to help the immune system remove harmful B cells more effectively. This approach is different from existing treatments and may provide a deeper and longer-lasting benefit.
Join our clinical trial
This is a first-in-human (FIH) study, meaning it is the first time the potential treatment is being tested in people. The study has been carefully designed with strict safety protocols and has been approved by an independent ethics committee. It is not known whether the study drug may cause unexpected, serious, or life-threatening side effects. While these are considered unlikely, you will be carefully monitored throughout the study and provided with prompt treatment if any such effects occur.
Before joining, you’ll receive detailed information about the study, meet with a doctor, and have the chance to ask any questions.
What to expect
- Participation in a monitored clinical environment
- Study visits scheduled
- Support from a professional medical team
- Reimbursement for your time and commitment
Study schedule
| Intake 1 | In-clinic stay:
26 August2026–30 August 2026 |
Follow-up visits:
31 August 2026– 19 November 2026 |
Study dates are subject to change. Our team will confirm details with you during the screening process.
Trial details
Study duration
- 4 night stay
- 8 follow-up visits
Study medication
The study drug is administered via subcutaneous injection
Additional eligibility
- Weigh between 55-100 kg
- Not pregnant or breastfeeding
- Willing to follow contraception guidelines (If applicable)
Ethics
The study has been carefully designed with strict safety protocols and has been approved by an independent ethics committee.
Are you a match?
Age
18 - 65 years old
Remuneration
Up to $6,300 *with screening reimbursement.
Full details outlined in consent form.
Gender
Male, Female or Female (Post-menopausal)
BMI
BMI 18 - 30 kg/m2
Commitment
4 nights, 8 clinic visits
Medical condition
Not taking any medications